eFFECTOR Therapeutics (EFTR) Insider Trading & Ownership $0.0002 0.00 (0.00%) As of 09:57 AM Eastern Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends eFFECTOR Therapeutics (NASDAQ:EFTR) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage4.70%Number OfInsiders Buying(Last 3 Years)4Amount OfInsider Buying(Last 3 Years)$189,272.75Number OfInsiders Selling(Last 3 Years)2Amount OfInsider Selling(Last 3 Years)$681,838.00 Get EFTR Insider Trade Alerts Want to know when executives and insiders are buying or selling eFFECTOR Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address EFTR Insider Buying and Selling by Quarter eFFECTOR Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/27/2023Sr One Capital Management, LlcMajor ShareholderSell24,366$15.25$371,581.50 10/4/2022Christopher B EhrlichDirectorBuy13$14.25$185.25 9/26/2022Christopher B EhrlichDirectorBuy754$13.75$10,367.50 8/3/2022Presidio Management Group X LlMajor ShareholderSell2,375$20.00$47,500.00 8/1/2022Presidio Management Group X LlMajor ShareholderSell1,068$19.75$21,093.00 7/27/2022Presidio Management Group X LlMajor ShareholderSell1,746$22.25$38,848.50 7/25/2022Presidio Management Group X LlMajor ShareholderSell91$23.25$2,115.75 7/22/2022Presidio Management Group X LlMajor ShareholderSell304$22.75$6,916.00 7/20/2022Presidio Management Group X LlMajor ShareholderSell401$25.00$10,025.00 7/18/2022Presidio Management Group X LlMajor ShareholderSell839$27.00$22,653.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 7/15/2022Presidio Management Group X LlMajor ShareholderSell1,836$27.75$50,949.00 6/23/2022Brian M Jr. GallagherDirectorBuy1,200$39.75$47,700.00 6/7/2022Michael ByrnesCFOBuy1,000$33.25$33,250.00 6/7/2022Stephen T WorlandInsiderBuy800$34.25$27,400.00 5/18/2022Presidio Management Group X LlMajor ShareholderSell563$43.25$24,349.75 5/16/2022Presidio Management Group X LlMajor ShareholderSell510$43.75$22,312.50 5/13/2022Presidio Management Group X LlMajor ShareholderSell904$46.00$41,584.00 5/11/2022Presidio Management Group X LlMajor ShareholderSell200$58.75$11,750.00 5/9/2022Presidio Management Group X LlMajor ShareholderSell160$63.50$10,160.00 2/18/2022Christopher B EhrlichDirectorBuy40$107.50$4,300.00 2/14/2022Christopher B EhrlichDirectorBuy80$111.25$8,900.00 2/8/2022Christopher B EhrlichDirectorBuy40$123.00$4,920.00 2/3/2022Christopher B EhrlichDirectorBuy200$128.75$25,750.00 1/27/2022Christopher B EhrlichDirectorBuy200$132.50$26,500.00 (Data available from 1/1/2013 forward) EFTR Insider Trading Activity - Frequently Asked Questions Who is on eFFECTOR Therapeutics's Insider Roster? The list of insiders at eFFECTOR Therapeutics includes Brian M Jr. Gallagher, Christopher B Ehrlich, Michael Byrnes, Presidio Management Group X Ll, Sr One Capital Management, Llc, and Stephen T Worland. Learn more on insiders at EFTR. What percentage of eFFECTOR Therapeutics stock is owned by insiders? 4.70% of eFFECTOR Therapeutics stock is owned by insiders. Learn more on EFTR's insider holdings. Which eFFECTOR Therapeutics insiders have been selling company stock? The following insider sold EFTR shares in the last 24 months: Sr One Capital Management, Llc ($371,581.50). How much insider selling is happening at eFFECTOR Therapeutics? Insiders have sold a total of 24,366 eFFECTOR Therapeutics shares in the last 24 months for a total of $371,581.50 sold. eFFECTOR Therapeutics Key ExecutivesDr. Stephen T. Worland Ph.D. (Age 66)CEO, President & Director Compensation: $873.96kMr. Michael Byrnes M.B.A. (Age 47)Chief Financial Officer Compensation: $654.82kDr. Douglas Warner M.D. (Age 52)Chief Medical Officer Compensation: $660.16kDr. Davide Ruggero Ph.D.Co-Founder and Member of Clinical & Scientific Advisory BoardDr. Kevan M. Shokat Ph.D.Co-Founder and Member of Clinical & Scientific Advisory Board More Insider Trading Tools from MarketBeat Related Companies AMPE Insider Transactions CALA Insider Transactions BTMDW Insider Transactions CLVRW Insider Transactions CLVR Insider Transactions FBIOP Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks With Strong Capital Returns and Insider Buying SignalsZymeworks in Focus for Insider Activity: Catalysts AheadInsiders Are Loading Up: 3 Key Stock Picks for InvestorsInsiders Are Selling, But These 3 Stocks Are Must-Buys3 Stocks That Wall Street Insiders Can’t Stop Buying This page (NASDAQ:EFTR) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eFFECTOR Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share eFFECTOR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
